Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4464323 | 1.00 | PEPD (0.48) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL336245 | 1.00 | PEPD (0.48) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL34169 | 0.95 | PEPD (0.43) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL130870 | 0.95 | PEPD (0.43) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL598373 | 0.95 | PEPD (0.43) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL10578737 | 0.95 | PEPD (0.43) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL9663237 | 0.93 | PEPD (0.42) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL11660179 | 0.93 | PEPD (0.42) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL10739888 | 0.93 | PEPD (0.42) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL7031195 | 0.93 | PEPD (0.42) | PEPDMEN1BLMKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | PEPD 1883/4885MEN1 3909/4885BLM 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.